MX2019010266A - Proceso para la preparacion de yoduro de 3,7-bis(dimetilamino)feno tiazin-5-ilio. - Google Patents

Proceso para la preparacion de yoduro de 3,7-bis(dimetilamino)feno tiazin-5-ilio.

Info

Publication number
MX2019010266A
MX2019010266A MX2019010266A MX2019010266A MX2019010266A MX 2019010266 A MX2019010266 A MX 2019010266A MX 2019010266 A MX2019010266 A MX 2019010266A MX 2019010266 A MX2019010266 A MX 2019010266A MX 2019010266 A MX2019010266 A MX 2019010266A
Authority
MX
Mexico
Prior art keywords
phenothiazin
dimethylamino
bis
preparing
ylium iodide
Prior art date
Application number
MX2019010266A
Other languages
English (en)
Inventor
Sayah Babak
Queru Stéphane
Feraud Michel
LAURENT Marina
Original Assignee
Provepharm Life Solutions
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provepharm Life Solutions filed Critical Provepharm Life Solutions
Publication of MX2019010266A publication Critical patent/MX2019010266A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B21/00—Thiazine dyes
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
    • C09B67/0096—Purification; Precipitation; Filtration
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Proceso para la preparación de yoduro de 3,7-bis(dimetilamino)feno tiazin-5-ilio, que permite lograr un alto grado de pureza, al mismo tiempo que es muy simple de implementar y tiene altos rendimientos. Este proceso utiliza fenotiazina como producto de partida y comprende las siguientes etapas: a) El tratamiento de fenotiazina con diyodo, b) El tratamiento del medio de reacción directamente de la etapa a) con dimetilamina.
MX2019010266A 2017-03-02 2018-02-16 Proceso para la preparacion de yoduro de 3,7-bis(dimetilamino)feno tiazin-5-ilio. MX2019010266A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1751700A FR3063495B1 (fr) 2017-03-02 2017-03-02 Procede de preparation de l’iodure de 3,7-bis(dimethylamino)phenothiazine-5-ylium
PCT/FR2018/050372 WO2018158520A1 (fr) 2017-03-02 2018-02-16 Procede de preparation de l'iodure de 3,7-bis(dimethylamino)phenothiazine-5-ylium

Publications (1)

Publication Number Publication Date
MX2019010266A true MX2019010266A (es) 2019-10-14

Family

ID=59031095

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010266A MX2019010266A (es) 2017-03-02 2018-02-16 Proceso para la preparacion de yoduro de 3,7-bis(dimetilamino)feno tiazin-5-ilio.

Country Status (17)

Country Link
US (2) US11078169B2 (es)
EP (1) EP3589622B1 (es)
JP (3) JP2020509019A (es)
KR (2) KR20230074848A (es)
CN (2) CN110382472B (es)
AU (1) AU2018228816B2 (es)
BR (1) BR112019018208A2 (es)
CA (1) CA3054659A1 (es)
DK (1) DK3589622T3 (es)
ES (1) ES2877117T3 (es)
FR (1) FR3063495B1 (es)
HU (1) HUE054691T2 (es)
MX (1) MX2019010266A (es)
PL (1) PL3589622T3 (es)
PT (1) PT3589622T (es)
RU (1) RU2768139C2 (es)
WO (1) WO2018158520A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3169480A1 (en) * 2020-02-28 2021-09-02 Janmejay R. VYAS A process for the preparation of methylene blue

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2373787A (en) 2001-03-08 2002-10-02 Univ Central Lancashire Phenothiazinium derivatives and their use to reduce pathogenic contaminants
CA2379211A1 (fr) 2002-03-28 2003-09-28 Institut De Cardiologie De Montreal Utilisation du bleu de methylene pour renverser la reaction hemodynamique exageree induite par la combinaison d'un derive nitre et du sildenafil ou d'une molecule de meme classe (inhibiteur de la phosphodiesterase)
RU2233274C1 (ru) * 2002-12-25 2004-07-27 Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" Способ получения 10-(3-диметиламино-2-метилпропил)-2-метоксифенотиазина
JP2007512297A (ja) * 2003-11-28 2007-05-17 フォトファーマイカ リミテッド 生物活性メチレンブルー誘導体（２）における開発
GB0327672D0 (en) * 2003-11-28 2003-12-31 Photopharmica Ltd Developments in biologically active methylene blue derivatives (phenothiazines)
PT1799662E (pt) 2004-09-23 2013-07-09 Wista Lab Ltd Métodos de síntese química e purificação de compostos de diaminofenotiazínio incluindo cloreto de metiltionínio (mtc)
PL2004155T3 (pl) * 2006-03-29 2018-08-31 Wista Laboratories Ltd. Inhibitory agregacji białek
DK2057136T3 (da) 2006-07-11 2013-08-26 Wista Lab Ltd Fremgangsmåde til syntese og/eller oprensning af diaminophenothiazinium forbindelser
FR2903696B1 (fr) 2006-07-12 2011-02-11 Provence Technologies Procede de purification de composes diaminophenothiazium
AU2016220096B2 (en) * 2015-02-17 2020-01-30 Arizona Board Of Regents On Behalf Of Arizona State University Phenothiazine analogues as mitochondrial therapeutic agents

Also Published As

Publication number Publication date
JP2022068343A (ja) 2022-05-09
RU2019126407A3 (es) 2021-04-27
KR102558527B1 (ko) 2023-07-21
US11078169B2 (en) 2021-08-03
CN110382472B (zh) 2023-05-09
DK3589622T3 (da) 2021-06-21
EP3589622A1 (fr) 2020-01-08
KR20230074848A (ko) 2023-05-31
AU2018228816B2 (en) 2021-09-30
WO2018158520A1 (fr) 2018-09-07
US11891367B2 (en) 2024-02-06
BR112019018208A2 (pt) 2020-06-23
RU2019126407A (ru) 2021-04-02
PT3589622T (pt) 2021-06-03
CN110382472A (zh) 2019-10-25
KR20190125366A (ko) 2019-11-06
EP3589622B1 (fr) 2021-03-31
CA3054659A1 (fr) 2018-09-07
JP2020509019A (ja) 2020-03-26
CN116410155A (zh) 2023-07-11
FR3063495A1 (fr) 2018-09-07
PL3589622T3 (pl) 2021-10-18
AU2018228816A1 (en) 2019-09-12
ES2877117T3 (es) 2021-11-16
RU2768139C2 (ru) 2022-03-23
FR3063495B1 (fr) 2019-04-05
JP2023011886A (ja) 2023-01-24
JP7482161B2 (ja) 2024-05-13
US20210323937A1 (en) 2021-10-21
US20200010438A1 (en) 2020-01-09
HUE054691T2 (hu) 2021-09-28

Similar Documents

Publication Publication Date Title
SA518400462B1 (ar) عمليات لتحضير أوليجومرات فوسفوروداي أميدات مورفولينو
SG10201808248RA (en) Deposition system with multi-cathode and method of manufacture thereof
PH12018500426A1 (en) Microorganism producing l-leucine and method of producing l-leucinie using the same
MX2019011759A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando el mismo.
MY195408A (en) Novel Aspartokinase Variant and Method for Producing L- Amino Acid Using the Same
SA518400500B1 (ar) عمليات لتحضير أوليجومرات
BR112018077067A2 (pt) processo para preparar um composto.
GB2588342B (en) Process that can withstand high currents, for producing ammonia
MX2018014123A (es) Procesos para preparar oligomeros de morfolino fosforodiamidato.
MX2019011758A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma.
MX2018009493A (es) Uso combinado de al menos una endoproteasa y al menos una exoproteasa en un proceso simultaneo de sacarificacion y fermentacion (ssf) para mejorar la produccion de etanol.
WO2018102070A3 (en) Bioelectrosynthesis of organic compounds
WO2016105172A3 (en) A method for preparing gadobutrol
MX2019011730A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma.
SA518400463B1 (ar) عمليات لتحضير أوليجومرات فوسفوروداي أميدات مورفولينو
MX2019010266A (es) Proceso para la preparacion de yoduro de 3,7-bis(dimetilamino)feno tiazin-5-ilio.
MX2018014160A (es) Procesos para preparar oligomeros de morfolino fosforodiamidato.
MX2016009347A (es) Proceso para la reconstitucion de una forma solida de una composicion farmaceutica.
MX2019012882A (es) Cepa de microbacterium y metodo para producir psicosa utilizando la misma.
MY195698A (en) Fermented Soybean Composition and Method for Producing Fermented Soybean Composition
MX366688B (es) Método y composición para mejorar la productividad de plantas no leguminosas.
MX2023010436A (es) Nueva variante de citrato sintasa y procedimiento para producir l-valina utilizando la misma.
MX2022002563A (es) Nuevo promotor y metodo para producir la sustancia deseada usando el mismo.
MY178533A (en) Manufacturing apparatus and manufacturing method for stretch-formed product
MX2021010633A (es) Procesos para producir trifluoroyodometano usando trifluoroacetatos de metal.